Augmentin ES-600 Cannot Be Prescribed for Children Over 40 kg
Augmentin ES-600 (600 mg/5 mL) is explicitly not approved for pediatric patients weighing 40 kg or more, and adults should not receive this formulation. 1
FDA-Approved Weight Restrictions
The FDA drug label for Augmentin ES-600 clearly states:
- Pediatric patients weighing 40 kg and more: Experience with AUGMENTIN ES-600 Powder for Oral Suspension in this group is not available 1
- Adults: Experience with AUGMENTIN ES-600 Powder for Oral Suspension in adults is not available and adults who have difficulty swallowing should not be given AUGMENTIN ES-600 Powder for Oral Suspension in place of the 500-mg or 875-mg tablet of AUGMENTIN 1
The dosing table provided in the FDA label stops at 36 kg (13.5 mL twice daily), with no guidance for heavier children 1.
Why This Restriction Exists
Augmentin ES-600 was specifically developed to provide high-dose amoxicillin (90 mg/kg/day) for recurrent or persistent acute otitis media in young children, particularly targeting drug-resistant Streptococcus pneumoniae and beta-lactamase-producing organisms 2, 3. The formulation contains 42.9 mg of clavulanic acid per 5 mL in a 14:1 ratio of amoxicillin to clavulanate 1, 2.
For children ≥40 kg, the volume required to achieve 90 mg/kg/day would be excessive and impractical. More importantly, no safety or efficacy data exist for this weight group with this specific formulation 1.
What to Prescribe Instead
For children weighing ≥40 kg who need amoxicillin/clavulanate:
- Use adult formulations: Standard Augmentin 500 mg or 875 mg tablets 1
- Alternative high-dose option: Augmentin XR 2000/125 mg twice daily (for adults and adolescents with drug-resistant respiratory infections) 4
- Standard dosing: Children ≥40 kg should be dosed as adults in most antibiotic guidelines 5, 6
Common Pitfall to Avoid
Do not attempt to extrapolate the ES-600 dosing beyond 40 kg. The suspension formulations are not interchangeable - ES-600 contains different amounts of clavulanic acid than the 200 mg/5 mL or 400 mg/5 mL suspensions, and substitution could lead to inappropriate clavulanate dosing 1.